Improving COVID-19 Treatment & Vaccine Development by Modulating the Immune Response: Applying Single-Cell Proteomics
On July 2nd, learn more about the Seattle Consortium, where several biotech and pharmaceutical companies have joined forces to investigate the molecular mechanisms of SARS-CoV-2 infection and to identify targets for medicines and vaccines. Some of the members of this Consortium are IsoPlexis, Merck, and the Institute for Systems Biology (ISB). Dr. James R. Heath, President of the Institute for Systems Biology will discuss key single cell learnings and applications from the large Seattle-based academic-pharmaceutical consortium committed to defining molecular mechanisms of SARS-CoV-2 infection and identifying potential prognostic immune biomarkers.
Topics that will be covered:
- Proteomic and genomic insights into COVID-19
- Mapping functional immune responses at the single-cell and serum level to study COVID-19
- Creating a balanced and durable immune response in COVID-19 patients using single-cell proteomics, leading to recovery and creating future vaccines and therapies for COVID-19